Drug intelligence / Profile preview

STT-5058

Development stage: Unknown
Lead developer: Staten Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

STT-5058 is a humanized monoclonal antibody that targets apolipoprotein C3 (ApoC3), a key regulator of triglyceride metabolism. By binding to novel and unique epitopes on ApoC3, STT-5058 acts as an inhibitor of this protein, aiming to lower triglyceride levels in the blood. The drug is designed as a "recycling" antibody with an extended half-life for improved therapeutic effect. It is being developed primarily for the treatment of dyslipidemia, particularly hypertriglyceridemia and mixed dyslipidemia in patients at high cardiovascular risk. STT-5058 was developed by Staten Biotechnology in collaboration with Novo Nordisk[2][3][6][8].

Other names: sst-5058sst5058sst 5058nn5058nn-5058nn 5058

Targets

APOC3 (Apolipoprotein C-III)

Beyond the preview

Go deeper on STT-5058.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STT-5058.

Explore the full profile